The aberrant expression of the C–C chemokine ligand 5/C–C chemokine receptor type 5 (CCL5-CCR5) axis has been recognized as a pivotal contributor to tumor progression, facilitating a more conducive TME for hematological malignancies and various solid tumors [74, 75]. Here, CCL5 is linked to hematologic disorder.